Evidence map›Paper›PMID 26489409›Full record

ArticleEuropean journal of medical research2015

PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China.

Yong Tao Li, Wei Hua Jiang, Xiao Wen Wang, Ming Shuai Zhang, Cheng Guang Zhang, Li Na Yi, Fulati WuwaliKhan, Aisikaer Ayoufu, Jiang Hua Ou

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Cancers · 2023
    Article
  4. Article
  5. Review
  6. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.International journal of molecular sciences · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yong Tao LiDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. lyt1822@sina.com.
Wei Hua JiangDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. jiangweihua2010@126.com.
Xiao Wen WangDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. wxwzx123@sina.com.
Ming Shuai ZhangDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. doctorzhangmingshuai@163.com.
Cheng Guang ZhangDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. liuheguang@163.com.
Li Na YiDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. nanazi@sina.com.
Fulati WuwaliKhanDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. fulatihao@163.com.
Aisikaer AyoufuDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. doctoraisikaer@126.com.
Jiang Hua OuDepartment of Breast Surgery, Cancer Hospital, Xinjiang Medical University, Urumqi, China. oujianghua@hotmail.com.
Tumor Hospital of Xinjiang Medical University · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGermline mutations in PALB2 gene make a small contribution to heritable breast cancer susceptibility. A recent report has revealed that women with mutations in the PALB2 gene were more than nine times as likely to develop breast cancer compared to those without. The aim of this study is to understand the status of PALB2 mutations among Chinese high-risk breast cancer patients in a multi-ethnic region in China.

methods152 patients with hereditary predisposition to breast cancer from the Xinjing region of China were enrolled in the study, and 100 control samples from healthy women were collected in the same locality. We sequenced the coding sequences and flanking intronic regions of PALB2 gene from DNA samples obtained from all subjects by direct sequencing.

resultsA total of 4 deleterious PALB2 mutations were identified in 152 breast cancer patients with a prevalence of about 2.6 % (4/152). The PALB2 mutation prevalence was 3.2 % (3/95) in cases with family history of breast cancer. In addition to the four deleterious mutations, we identified nine missense variants in 12 patients, using the prediction Softwares SIFT and PolyPhen, four of which might be disease associated (in 5 patients). Two of the 4 patients with deleterious mutations and 2 of the 5 patients presenting putative deleterious missense mutations had triple-negative breast cancer. No PALB2 mutation carriers were identified in 100 healthy controls.

conclusionPALB2 mutations account for a small, but not negligible, proportion of patients with hereditary predisposition to breast cancer in the Xinjing region of China.

Indexed as

MutationAdultAgedAsian PeopleBreast NeoplasmsChinaFanconi Anemia Complementation Group N ProteinFemaleGenetic Predisposition to DiseaseHumansMiddle AgedNuclear ProteinsTumor Suppressor ProteinsFanconi Anemia Complementation Group N ProteinNuclear ProteinsPALB2 protein, humanTumor Suppressor Proteins

Identifiers

PMID26489409
PMCPMC4618884
OpenAlexW2135057265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.